| dc.description.abstract | Background: The Oncotype Dx recurrence score (ODx-RS) guides the adjuvant chemotherapy decision-making process for patients with early-stage hormone receptor-positive, HER-2 receptor-negative breast cancer. This study aimed to evaluate survival and its correlation with ODx-RS in pT1-2, N0-N1mic patients treated with adjuvant therapy based on tumor board decisions. Patients and methods: Estrogen-positive HER-2 negative early-stage breast cancer patients (pT1-2 N0, N1mic) with known ODx-RS, operated on between 2010 and 2014, were included in this study. The primary aim was to evaluate 5-year disease-free survival (DFS) rates according to ODX-RS. Results: A total of 203 eligible patients were included in the study, with a median age of 48 (range 26-75) and median follow-up of 84 (range 23-138) months. ROC curve analysis for all patients revealed a recurrence cut-off age of 45 years, prompting evaluation by grouping patients as <= 45 years vs. >45 years. No significant difference in five-year DFS rates was observed between the endocrine-only (ET) and chemo-endocrine (CE) groups. However, among the ET group, DFS was higher in patients over 45 years compared to those aged <= 45 years. When stratifying by ODx-RS as 0-17 and >= 18, DFS was significantly higher in the former group within the ET group. However, such differences were not seen in the CE group. In the ET group, an ODx-RS >= 18 and menopausal status were identified as independent factors affecting survival, with only an ODx-RS >= 18 impacting DFS in patients aged <= 45 years. The ROC curve analysis for this subgroup found the ODx-RS cut-off to be 18. Conclusion: This first multicenter Oncotype Dx survival analysis in Turkey demonstrates the importance of Oncotype Dx recurrence score and age in determining treatment strategies for early-stage breast cancer patients. As a different aproach to the literature, our findings suggest that the addition of chemotherapy to endocrine therapy in young patients (<= 45 years) with Oncotype Dx recurrence scores of >= 18 improves DFS. | en_US |
| dc.department-temp | [Unal, Caglar] Kartal Dr Lutfi Kirdar City Hosp, Dept Internal Med, Div Med Oncol, Istanbul, Turkiye; [Ozmen, Tolga] Harvard Med Sch, Div Gastrointestinal & Oncol Surg, Boston, MA USA; [Ozmen, Tolga] Massachusetts Gen Hosp, Div Gastrointestinal & Oncol Surg, Boston, MA USA; [Ordu, Cetin] Gayrettepe Florence Nightingale Hosp, Dept Internal Med, Div Med Oncol, Istanbul, Turkiye; [Pilanci, Kezban Nur] Mem Bahcelievler Hosp, Dept Internal Med, Div Med Oncol, Istanbul, Turkiye; [Ilgun, Ahmet Serkan] Mater Dei Hosp, Dept Surg, Msida, Malta; [Gokmen, Erhan] Ege Univ, Sch Med, Dept Internal Med, Div Med Oncol, Izmir, Turkiye; [Almuradova, Elvina] Tinaztepe Galen Bayrakli Hosp, Dept Internal Med, Div Med Oncol, Izmir, Turkiye; [Ozdogan, Mustafa] Akdeniz Univ, Dept Internal Med, Div Med Oncol, Antalya, Turkiye; [Guler, Niluefer] Hacettepe Univ, Inst Oncol, Dept Internal Med, Div Med Oncol, Ankara, Turkiye; [Uras, Cihan; Kara, Halil] Acibadem Univ, Dept Gen Surg, Istanbul, Turkiye; [Demircan, Orhan] Cukurova Univ, Sch Med, Dept Gen Surg, Adana, Turkiye; [Isik, Selver] Marmara Univ Hosp, Dept Internal Med, Div Med Oncol, Istanbul, Turkiye; [Alco, Gul] Gayrettepe Florence Nightingale Hosp, Dept Radiat Oncol, Istanbul, Turkiye; [Saip, Pinar; Aydin, Esra] Istanbul Univ, Inst Oncol, Dept Internal Med, Div Med Oncol, Istanbul, Turkiye; [Duymaz, | en_US |
